

Kaveri et al. 10/031,938

characterized in that it comprises a protease inhibitor. Examples of protease inhibitors that can be used as anti-Factor VIII allo-antibody catalysed Factor VIII degradation inhibitors within the context of the present invention, without being limited thereto, are fluorophosphate-type inhibitors, such as DFP for example, or sulphonyl fluoride-type inhibitors, such as PMSF or AEBSF (4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride (notably marked by Roche Diagnostics GmbH, Mannheim, Germany, under the trademark Pefabloc®)), for example. More particularly, this inhibitor is characterized in that said inhibitor inhibits cleavage of the scissile bonds : Arg³⁷²-Ser³⁷³, located between the A1 and A2 domains, Tyr¹⁶⁸⁰-Asp¹⁶⁸¹, located on the N-terminus of the A3 domain, and the Glu¹⁷⁹⁴ – Asp¹⁷⁹⁵ located within the A3 domain of the Factor VIII molecule. More preferably still, this inhibitor is characterized in that it comprises a peptide or non-peptide analogue of the amino acid sequence:

Ser Val Ala Lys Lys His Pro ;

a peptide or non-peptide analogue of the amino acid sequence :

Asp Glu Asp Glu Asn Gln Ser ; or

a peptide or non-peptide analogue of the amino acid sequence :

Asp Gln Arg Gln Gly Ala Glu .

On page 20, please delete the existing table and replace it with the following table:

Amino acid sequence	Cleavage site
Ser Val Ala Lys Lys His Pro (SVAKKHP)	Arg ³⁷² – Ser ³⁷³ (R ³⁷² – S ³⁷³)
Asp Gln Arg Gln Gly Ala Glu (DQRQGAE)	Glu ¹⁷⁹⁴ – Asp ¹⁷⁹⁵ (E ¹⁷⁹⁴ – D ¹⁷⁹⁵)
Asp Glu Asp Glu Asn Gln Ser (DEDENQS)	Tyr ¹⁶⁸⁰ – Asp ¹⁶⁸¹ (Y ¹⁶⁸⁰ – D ¹⁶⁸¹)